Australia's most trusted
source of pharma news
Thursday, 06 February 2025
Posted 4 February 2025 AM
Novartis appears to have pulled off its shift to a 'pure-play' strategy generating net sales of US$50.3 billion in 2024 - one of the company's best earnings in recent years.
In 2023, the company completed a long-term restructuring process that saw it integrate its pharmaceuticals and oncology business units into an innovative medicines unit, and focus on five therapeutic areas: cardiovascular, immunology, neuroscience, solid tumours and haematology.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.